Exome Asset Management
Latest statistics and disclosures from Exome Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PRAX, COGT, ELVN, IONS, XBI, and represent 25.82% of Exome Asset Management's stock portfolio.
- Added to shares of these 10 stocks: XBI (+$7.7M), INSM, MLTX, Cytokinetics, RYTM, BSX, ALKS, Beigene Ltd call, GLUE, CBIO.
- Started 22 new stock positions in LPCN, RLAY, BSX, Soleno Therapeutics, Cytokinetics, GLUE, ZBIO, AVTX, INSM, RYTM. Ideaya Biosciences, MAZE, XBI, Liquidia Technologies, ALKS, MLTX, Wave Life Sciences Ltd put, Centessa Pharmaceuticals, Compass Therapeutics, CBIO, Beigene Ltd call, FDMT.
- Reduced shares in these 10 stocks: WVE (-$7.2M), AstraZeneca (-$5.3M), , PRAX, IMVT, UHS, IRON, CELC, TVTX, DXCM.
- Sold out of its positions in Aldeyra Therapeutics, AstraZeneca, BLTE, CELC, DXCM, IRON, Disc Medicine, EWTX, FULC, GOSS.
- Exome Asset Management was a net seller of stock by $-25M.
- Exome Asset Management has $193M in assets under management (AUM), dropping by -7.55%.
- Central Index Key (CIK): 0002011932
Tip: Access up to 7 years of quarterly data
Positions held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Exome Asset Management
Exome Asset Management holds 55 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines I Com New (PRAX) | 7.6 | $15M | -21% | 46k | 322.19 |
|
| Cogent Biosciences (COGT) | 5.5 | $11M | -8% | 279k | 38.49 |
|
| Enliven Therapeutics (ELVN) | 4.5 | $8.6M | 220k | 39.20 |
|
|
| Ionis Pharmaceuticals (IONS) | 4.3 | $8.3M | -5% | 110k | 75.09 |
|
| Spdr Series Trust State Street Spd Put Option (XBI) | 4.0 | $7.7M | NEW | 60k | 127.73 |
|
| Guardant Health (GH) | 4.0 | $7.6M | -15% | 83k | 92.37 |
|
| Cytokinetics Com New (CYTK) | 3.5 | $6.8M | -16% | 104k | 65.91 |
|
| Eli Lilly & Co. (LLY) | 3.3 | $6.4M | -10% | 7.0k | 919.77 |
|
| Alumis (ALMS) | 3.2 | $6.2M | -4% | 279k | 22.03 |
|
| Bridgebio Pharma (BBIO) | 2.6 | $5.0M | -16% | 68k | 74.26 |
|
| Vera Therapeutics Cl A (VERA) | 2.4 | $4.6M | -7% | 115k | 40.23 |
|
| Insmed Com Par $.01 (INSM) | 2.3 | $4.4M | NEW | 27k | 163.52 |
|
| Anthem (ELV) | 2.2 | $4.3M | -14% | 15k | 292.75 |
|
| Agios Pharmaceuticals (AGIO) | 2.2 | $4.2M | -8% | 125k | 33.83 |
|
| United Therapeutics Corporation (UTHR) | 2.2 | $4.2M | -8% | 7.1k | 592.98 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 2.1 | $4.0M | NEW | 215k | 18.64 |
|
| Cytokinetics Put Put Option | 2.0 | $4.0M | NEW | 60k | 65.91 |
|
| Natera (NTRA) | 1.9 | $3.7M | 19k | 199.99 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 1.8 | $3.5M | NEW | 41k | 86.97 |
|
| UnitedHealth (UNH) | 1.8 | $3.5M | +120% | 13k | 270.59 |
|
| Apellis Pharmaceuticals | 1.8 | $3.4M | -37% | 86k | 40.23 |
|
| Verastem Com New (VSTM) | 1.7 | $3.4M | +58% | 637k | 5.30 |
|
| 10x Genomics Cl A Com (TXG) | 1.7 | $3.3M | -5% | 154k | 21.23 |
|
| Boston Scientific Corporation (BSX) | 1.6 | $3.0M | NEW | 48k | 62.75 |
|
| Alkermes SHS (ALKS) | 1.5 | $3.0M | NEW | 84k | 35.36 |
|
| Beone Medicines Call Call Option | 1.5 | $3.0M | NEW | 10k | 296.97 |
|
| Monte Rosa Therapeutics (GLUE) | 1.5 | $3.0M | NEW | 180k | 16.45 |
|
| Intuitive Surgical Com New (ISRG) | 1.5 | $2.9M | 6.4k | 460.99 |
|
|
| Adagene Ads (ADAG) | 1.5 | $2.9M | -30% | 737k | 3.92 |
|
| Arrowhead Pharmaceuticals (ARWR) | 1.5 | $2.9M | -8% | 46k | 62.70 |
|
| Crescent Biopharma (CBIO) | 1.5 | $2.8M | NEW | 153k | 18.37 |
|
| Relay Therapeutics (RLAY) | 1.4 | $2.8M | NEW | 278k | 9.95 |
|
| Ideaya Biosciences Call Call Option | 1.4 | $2.7M | NEW | 80k | 33.32 |
|
| Maze Therapeatics (MAZE) | 1.4 | $2.6M | NEW | 89k | 29.85 |
|
| Cytomx Therapeutics (CTMX) | 1.3 | $2.5M | -30% | 522k | 4.70 |
|
| Avalo Therapeutics Com New (AVTX) | 1.2 | $2.4M | NEW | 159k | 14.93 |
|
| Alumis Put Put Option | 1.2 | $2.3M | +97% | 105k | 22.03 |
|
| Glaukos (GKOS) | 1.2 | $2.2M | -33% | 21k | 107.66 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.1 | $2.2M | +67% | 234k | 9.39 |
|
| Penumbra (PEN) | 1.1 | $2.1M | -30% | 6.3k | 328.37 |
|
| Soleno Therapeutics | 1.1 | $2.1M | NEW | 62k | 33.48 |
|
| Liquidia Corporation Com New (LQDA) | 0.9 | $1.7M | -49% | 46k | 37.74 |
|
| Zenas Biopharma (ZBIO) | 0.8 | $1.6M | NEW | 81k | 19.55 |
|
| Liquidia Corporation Put Put Option | 0.8 | $1.5M | NEW | 40k | 37.74 |
|
| Novabridge Biosciences Sponsored Ads (NBP) | 0.7 | $1.4M | +15% | 577k | 2.46 |
|
| Centessa Pharmaceuticals Put Put Option | 0.7 | $1.4M | NEW | 35k | 39.72 |
|
| 4d Molecular Therapeutics In (FDMT) | 0.6 | $1.2M | NEW | 131k | 9.31 |
|
| Nextcure Com New (NXTC) | 0.6 | $1.2M | -30% | 116k | 10.52 |
|
| Palisade Bio (PALI) | 0.5 | $1.1M | -20% | 600k | 1.75 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.4 | $744k | 13k | 56.78 |
|
|
| Travere Therapeutics Put Put Option | 0.3 | $594k | -73% | 20k | 29.71 |
|
| Lipocine Com New (LPCN) | 0.3 | $486k | NEW | 61k | 7.99 |
|
| Arbutus Biopharma (ABUS) | 0.2 | $340k | 76k | 4.50 |
|
|
| Wave Life Sciences Put Put Option | 0.1 | $218k | NEW | 30k | 7.25 |
|
| Compass Therapeutics Call Call Option | 0.1 | $133k | NEW | 25k | 5.29 |
|
Past Filings by Exome Asset Management
SEC 13F filings are viewable for Exome Asset Management going back to 2023
- Exome Asset Management 2026 Q1 filed May 15, 2026
- Exome Asset Management 2025 Q4 filed Feb. 13, 2026
- Exome Asset Management 2025 Q3 filed Nov. 14, 2025
- Exome Asset Management 2025 Q2 restated filed Aug. 15, 2025
- Exome Asset Management 2025 Q1 restated filed May 16, 2025
- Exome Asset Management 2025 Q1 filed May 15, 2025
- Exome Asset Management 2024 Q4 filed Feb. 14, 2025
- Exome Asset Management 2024 Q3 amended filed Dec. 13, 2024
- Exome Asset Management 2024 Q2 restated filed Oct. 3, 2024
- Exome Asset Management 2024 Q2 filed Aug. 14, 2024
- Exome Asset Management 2024 Q1 filed May 15, 2024
- Exome Asset Management 2023 Q4 filed Feb. 15, 2024